文献速递消化系统肿瘤

一线纳武利尤单抗联合瑞拉利单抗加化疗治疗胃或胃食管结合部腺癌:II期RELATIVITY-060研究

First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
PubMed 文献 · J Clin Oncol · 2024-05-09

RELATIVITY-060是一项开放标签II期研究,将274例初治晚期胃/胃食管结合部腺癌患者随机1:1分配至纳武利尤单抗+瑞拉利单抗+化疗组(138例)或纳武利尤单抗+化疗组(136例)。在LAG-3表达≥1%患者中,主要终点盲法独立中心评审(BICR)评估的客观缓解率(ORR)分别为48%和61%,研究未达到主要终点。

要点

  • 在LAG-3表达≥1%患者中,纳武利尤单抗+瑞拉利单抗+化疗组BICR评估ORR为48%,纳武利尤单抗+化疗组为61%。
  • 中位无进展生存期分别为7.0个月和8.3个月(HR 1.41,95%CI 0.97-2.05),中位总生存期分别为13.5个月和16.0个月(HR 1.04,95%CI 0.70-1.54)。
  • 3级或4级治疗相关不良事件发生率分别为69%和61%,因任何级别治疗相关不良事件停药率分别为42%和36%。

核心结论

  • 在LAG-3表达≥1%患者中,与纳武利尤单抗+化疗相比,加用瑞拉利单抗未改善ORR,研究未达到主要终点。
  • 需进一步研究以明确在抗PD-1联合化疗基础上加用抗LAG-3能否使特定胃/胃食管结合部腺癌患者亚组获益。

研究设计与样本

  • 开放标签II期RELATIVITY-060研究,纳入不可切除局部晚期或转移性胃/胃食管结合部腺癌初治患者。
  • 共274例患者随机1:1分配至纳武利尤单抗+瑞拉利单抗(固定剂量复方)+化疗组(138例)或纳武利尤单抗+化疗组(136例)。
  • 主要终点为LAG-3表达≥1%患者中盲法独立中心评审(BICR)按RECIST v1.1评估的客观缓解率(ORR)。
  • 中位随访时间为11.9个月。

主要发现

  • 在LAG-3表达≥1%患者中,BICR评估的ORR(95%CI)在纳武利尤单抗+瑞拉利单抗+化疗组为48%(38至59),在纳武利尤单抗+化疗组为61%(51至71)。
  • BICR评估的中位无进展生存期(95%CI)分别为7.0个月(5.8至8.4)和8.3个月(6.9至12.1),HR为1.41(95%CI 0.97至2.05)。
  • 中位总生存期(95%CI)分别为13.5个月(11.9至19.1)和16.0个月(10.9至不可估计),HR为1.04(95%CI 0.70至1.54)。
  • 在所有接受治疗患者中,3级或4级治疗相关不良事件发生率分别为69%和61%。
  • 因任何级别治疗相关不良事件停药的患者比例分别为42%和36%。

局限性

  • 需进一步研究以明确在抗PD-1联合化疗基础上加用抗LAG-3能否使特定胃/胃食管结合部腺癌患者亚组获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Open-label phase II study (RELATIVITY-060) to investigate the efficacy and safety of first-line nivolumab, a PD-1-blocking antibody, plus relatlimab, a lymphocyte-activation gene 3 (LAG-3)-blocking antibody, plus chemotherapy in patients with previously untreated advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC). METHODS: Patients with unresectable, locally advanced or metastatic GC/GEJC were randomly assigned 1:1 to nivolumab + relatlimab (fixed-dose combination) + chemotherapy or nivolumab + chemotherapy. The primary end point was objective response rate (ORR; per RECIST v1.1 by blinded independent central review [BICR]) in patients whose tumors had LAG-3 expression ≥1%. RESULTS: Of 274 patients, 138 were randomly assigned to nivolumab + relatlimab + chemotherapy and 136 to nivolumab + chemotherapy. Median follow-up was 11.9 months. In patients with LAG-3 expression ≥1%, BICR-assessed ORR (95% CI) was 48% (38 to 59) in the nivolumab + relatlimab + chemotherapy arm and 61% (51 to 71) in the nivolumab + chemotherapy arm; median progression-free survival (95% CI) by BICR was 7.0 months (5.8 to 8.4) versus 8.3 months (6.9 to 12.1; hazard ratio [HR], 1.41 [95% CI, 0.97 to 2.05]), and median overall survival (95% CI) was 13.5 months (11.9 to 19.1) versus 16.0 months (10.9 to not estimable; HR, 1.04 [95% CI, 0.70 to 1.54]), respectively. Grade 3 or 4 treatment-related adverse events (TRAEs) occurred in 69% and 61% of all treated patients, and 42% and 36% of patients discontinued because of any-grade TRAEs in the nivolumab + relatlimab + chemotherapy and nivolumab + chemotherapy arms, respectively. CONCLUSION: RELATIVITY-060 did not meet its primary end point of improved ORR in patients with LAG-3 expression ≥1% when relatlimab was added to nivolumab + chemotherapy compared with nivolumab + chemotherapy. Further studies are needed to address whether adding anti-LAG-3 to anti-PD-1 plus chemotherapy can benefit specific GC/GEJC patient subgroups.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hegewisch-Becker S, Mendez G, Chao J, et al. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. J Clin Oncol. 2024. PMID: 38723227. doi:10.1200/JCO.23.01636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。